GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Median PS Value

3D Medicines (HKSE:01244) Median PS Value : HK$0.00 (As of Jun. 05, 2024)


View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. 3D Medicines's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$3.046. 3D Medicines's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is HK$0.00.

As of today (2024-06-05), 3D Medicines's share price is HK$6.30. 3D Medicines's Median PS Value is HK$0.00. Therefore, 3D Medicines's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for 3D Medicines's Median PS Value or its related term are showing as below:

HKSE:01244's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.67
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

3D Medicines Median PS Value Historical Data

The historical data trend for 3D Medicines's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines Median PS Value Chart

3D Medicines Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Median PS Value
- - - -

3D Medicines Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Median PS Value Get a 7-Day Free Trial - - - - -

Competitive Comparison of 3D Medicines's Median PS Value

For the Biotechnology subindustry, 3D Medicines's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3D Medicines's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3D Medicines's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where 3D Medicines's Price-to-Median-PS-Value falls into.



3D Medicines Median PS Value Calculation

3D Medicines's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=3.046*0
=0.00

10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 3D Medicines's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$3.046.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


3D Medicines  (HKSE:01244) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

3D Medicines's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=6.30/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


3D Medicines Median PS Value Related Terms

Thank you for viewing the detailed overview of 3D Medicines's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


3D Medicines (HKSE:01244) Business Description

Traded in Other Exchanges
N/A
Address
No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN
3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.
Executives
Gong Zhaolong 2101 Beneficial owner
Zhu Pai 2101 Beneficial owner
Dragon Prosper Holdings Limited 2101 Beneficial owner
Simcere Pharmaceutical Group Limited 2101 Beneficial owner
Gong Zhaolong 2501 Other
Immunal Medixin Us Limited 2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership) 2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd. 2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.) 2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership) 2201 Interest of corporation controlled by you
Zhu Jinqiao 2103 Interests held jointly with another person

3D Medicines (HKSE:01244) Headlines

No Headlines